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Abstract: BACKGROUND The value of standard 2-dimensional transthoracic echocardiographic param-
eters for risk stratification in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC/D) is controversial. METHODS AND RESULTS We investigated the impact of RV fractional
area change (FAC) and tricuspid annulus plane systolic excursion (TAPSE) for the prediction of major
adverse cardiovascular events (MACE) defined as the occurrence of cardiac death, heart transplantation,
survived sudden cardiac death, ventricular fibrillation, sustained ventricular tachycardia, or arrhythmo-
genic syncope. Among 70 patients who fulfilled the 2010 ARVC/D Revised Task Force Criteria and
underwent baseline transthoracic echocardiography, 37 (53%) patients experienced MACE during a me-
dian follow-up period of 5.3 (interquartile range, 1.8-9.8) years. Average values for FAC, TAPSE, and
TAPSE indexed to body surface area (BSA) decreased over time (P=0.03 for FAC, P=0.03 for TAPSE,
and P=0.01 for TAPSE/BSA, each versus baseline). In contrast, median RV end-diastolic area increased
(P=0.001 versus baseline). Based on the results of Kaplan-Meier estimates, the time between baseline
transthoracic echocardiography and experiencing MACE was significantly shorter for patients with FAC
<23% (P<0.001), TAPSE <17 mm (P=0.02), or right atrial short axis/BSA ￿25 mm/m(2) (P=0.04)
at baseline. A reduced FAC constituted the strongest predictor of MACE (hazard ratio, 1.08 per 1%
decrease; 95% confidence interval, 1.04-1.12; P<0.001) on bivariable analysis. CONCLUSIONS This
long-term observational study indicates that TAPSE and dilation of right-sided cardiac chambers are
associated with an increased risk for MACE in patients with ARVC/D with advanced disease and a high
risk for adverse events. However, FAC is the strongest echocardiographic predictor of adverse outcome
in these patients. Our data advocate a role for transthoracic echocardiography in risk stratification in
patients with ARVC/D, although our results may not be generalizable to lower-risk ARVC/D cohorts.
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Arrhythmogenic right ventricular cardiomyopathy/dyspla-sia (ARVC/D) is an inherited disease characterized by a 
progressive fibrofatty replacement mainly involving the RV 
myocardium. It is associated with ventricular arrhythmias, 
heart failure, and sudden cardiac death (SCD).1–6
Clinical Perspective on p 239
RV dilation, reduced RV systolic function, and diffuse RV 
involvement have previously been studied as predictors of an 
adverse outcome in patients with ARVC/D but have yielded 
conflicting results possibly because of divergent imaging 
modalities, varying parameters measured, and heteroge-
neous patient cohorts.7–15 Data about the predictive role of 
RV fractional area change (FAC) in ARVC/D as measured by 
2-dimensional transthoracic echocardiography (2D TTE) are 
scarce and controversial.9,14–20
Tricuspid annulus plane systolic excursion (TAPSE) can eas-
ily be determined by M-mode TTE. It is a robust parameter for 
Background—The value of standard 2-dimensional transthoracic echocardiographic parameters for risk stratification in 
patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is controversial.
Methods and Results—We investigated the impact of RV fractional area change (FAC) and tricuspid annulus plane systolic 
excursion (TAPSE) for the prediction of major adverse cardiovascular events (MACE) defined as the occurrence of cardiac 
death, heart transplantation, survived sudden cardiac death, ventricular fibrillation, sustained ventricular tachycardia, or 
arrhythmogenic syncope. Among 70 patients who fulfilled the 2010 ARVC/D Revised Task Force Criteria and underwent 
baseline transthoracic echocardiography, 37 (53%) patients experienced MACE during a median follow-up period of 5.3 
(interquartile range, 1.8–9.8) years. Average values for FAC, TAPSE, and TAPSE indexed to body surface area (BSA) 
decreased over time (P=0.03 for FAC, P=0.03 for TAPSE, and P=0.01 for TAPSE/BSA, each versus baseline). In contrast, 
median RV end-diastolic area increased (P=0.001 versus baseline). Based on the results of Kaplan–Meier estimates, the 
time between baseline transthoracic echocardiography and experiencing MACE was significantly shorter for patients 
with FAC <23% (P<0.001), TAPSE <17 mm (P=0.02), or right atrial short axis/BSA ≥25 mm/m2 (P=0.04) at baseline. A 
reduced FAC constituted the strongest predictor of MACE (hazard ratio, 1.08 per 1% decrease; 95% confidence interval, 
1.04–1.12; P<0.001) on bivariable analysis.
Conclusions—This long-term observational study indicates that TAPSE and dilation of right-sided cardiac chambers are 
associated with an increased risk for MACE in patients with ARVC/D with advanced disease and a high risk for adverse 
events. However, FAC is the strongest echocardiographic predictor of adverse outcome in these patients. Our data advocate 
a role for transthoracic echocardiography in risk stratification in patients with ARVC/D, although our results may not be 
generalizable to lower-risk ARVC/D cohorts.  (Circ Cardiovasc Imaging. 2014;7:230-239.)
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echocardiographic assessment of RV longitudinal systolic func-
tion if properly acquired and closely correlates with RV ejection 
fraction (RVEF); however, it has not been studied as a prognostic 
measure in ARVC/D so far.18,21–23 Therefore, the purpose of this 
longitudinal study was to (1) describe the change of FAC and 
TAPSE among other conventional echocardiographic param-
eters during long-term follow-up, and (2) define their prognostic 
value in a relatively large cohort of patients with ARVC/D.
Methods
Patient Population
The Zurich ARVC Program (www.arvc.ch) was established in 2011 
to provide expert clinical care for patients with ARVC/D. Patients 
were recruited at 3 collaborative Swiss centers (University Hospital 
Zurich, University Hospital Bern, and Triemli Hospital Zurich). So 
far, the Zurich ARVC Program has recruited 131 patients ≥15 years 
of age with a possible, borderline, or definite diagnosis of ARVC/D 
according to the 2010 Revised Task Force Criteria (TFC).24 For this 
study, only patients with a definite or borderline diagnosis, echocardio-
graphic assessment at baseline including measurements of both FAC 
and TAPSE, and a follow-up duration of ≥3 months were included. 
Furthermore, patients in whom diagnosis was made by the inclusion of 
FAC were excluded from the current analysis to avoid interaction bias 
with disease probability within the Cox proportional hazard model. 
Thus, within this study, we report data from 70 patients that fulfilled 
the inclusion criteria (Figure 1). TTE at baseline was defined as the first 
TTE in which measurements of both FAC and TAPSE were available. 
There was no patient in whom diagnosis of ARVC/D was based on a 
reduced RVEF as detected by cardiac magnetic resonance (CMR) to-
mography. Echocardiography was prospectively analyzed in 28 (40%) 
and retrospectively analyzed in 42 (60%) patients. Echocardiographic 
data were interpreted by 2 different observers blinded to the outcome 
data and to each other. Clinical information regarding demographics 
and symptoms was obtained from hospital records at the time of base-
line TTE. This study was approved by the institutional review board of 
each participating center, and in accordance with Swiss law, patients 
gave written informed consent for prospective inclusion into this study.
Echocardiography
From left parasternal, apical, and subcostal windows, conventional 
M-mode, 2D, and color Doppler echocardiography was performed 
by an experienced investigator trained in the analysis of the com-
plex anatomy of the right ventricle in all patients using ultrasound 
transducers with a frequency range between 1 and 5 MHz (Acuson 
Sequoia C 512; Acuson Corporation, Siemens, Mountain View, 
CA; Vivid 7 or Vivid E9; GE Vingmed Ultrasound AS, Horten, 
Norway; iE33; Philips Healthcare, Best, the Netherlands) and ac-
cording to a standard clinical protocol that did not differ among 
the 3 centers. Dimensions and function of both ventricles were as-
sessed according to established guidelines for 2D TTE.25 For FAC, 
final values were obtained after averaging 2 measurements over 
1 cardiac cycle, whereas for all other parameters, 1 measurement 
was taken. The degree of tricuspid regurgitation was determined as 
none, mild, moderate, or severe.26
Figure 1. Flow chart. ARVC/D indicates arrhythmogenic right 
ventricular cardiomyopathy/dysplasia; FAC, fractional area 
change; and TTE, transthoracic echocardiography.
Figure 2. Representative echocardiographic end-diastolic (area 
D; top) and end-systolic (area S; middle) right ventricular area 
measurements (blue lines) taken from the apical 4-chamber view 
in a patient with definite arrhythmogenic right ventricular cardio-
myopathy/dysplasia. M-mode of the lateral tricuspid annular sys-
tolic excursion for the measurement of tricuspid annulus plane 
systolic excursion (tricuspid annulus plane systolic excursion, 
TAPSE; bottom) in this same patient (blue line). FAC indicates 
fractional area change. 
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RV Measurements
Echocardiography-derived 2D RV area measurements were taken 
from the apical 4-chamber view (4CV) at end-diastole (area D) 
and end-systole (area S), and FAC was defined as the ratio between 
the difference of the end-diastolic and end-systolic RV areas and 
the end-diastolic area (FAC=[area D−area S]/area D) as previ-
ously reported (Figure 2).9,23 TAPSE was determined by placing 
the M-mode cursor perpendicularly through the lateral tricuspid 
annulus in the 4CV and measuring the amount of longitudinal mo-
tion at peak systole (Figure 2).17,23 A FAC ≥33%14,24 and a TAPSE 
≥17 mm27 were considered normal. Echocardiographic exams and 
reports were also reviewed for regional wall motion abnormalities 
and left ventricular (LV) involvement. LV involvement was con-
sidered when regional wall motion abnormalities or a reduced EF 
(<50% by Simpson biplane method) were present and other causes 
were excluded.9,14
Reproducibility
To determine intra- and interobserver variability, measurements were 
reanalyzed by the same observer (at least 1 week after the first mea-
surement) and by an independent observer in 31 randomly selected 
cases.
Follow-Up and Definitions
Follow-up for survival data was performed by review of hospital 
charts, including implantable cardioverter defibrillator (ICD) inter-
rogations with stored electrograms, Holter ECGs, clinical visits, and 
telephonic interviews of patients, their relatives, or treating physi-
cians. The role of FAC, TAPSE, and other parameters on long-term 
clinical outcome was compared in 2 patient groups: (1) patients with 
major adverse cardiovascular events (MACE)—adverse outcome 
(composite of cardiac death, heart transplantation, survived SCD, 
ventricular fibrillation [VF], sustained ventricular tachycardia [VT], 
and arrhythmogenic syncope), and (2) all remaining patients—favor-
able outcome. For Kaplan–Meier estimates and Cox regression anal-
yses, time from baseline to MACE was the event of interest. Survived 
SCD, VF, sustained VT, and arrhythmogenic syncope were defined as 
previously reported.28
Statistical Analysis
Continuous variables are presented as mean±SD or median (inter-
quartile range [ICR]). Categorical variables are reported as frequency 
(percentage). Comparisons between groups with a favorable outcome 
and MACE (Tables 1 and 2) were performed by the 2-sided unpaired 
Student t-test (normal distribution) or the Mann–Whitney U-test 
(skewed distribution) for continuous variables, and by Fisher exact 
Table 1. Baseline Clinical Characteristics
Patient Characteristics
All Patients 
(n=70)
Outcome
P Value
Favorable  
(n=33)
MACE  
(n=37)
Men, n (%) 47 (67%) 26 (79%) 21 (57%) 0.07
Age, y, mean±SD 42.9±14.7 45.5±13.9 40.6±15.2 0.17
Systolic blood pressure, mm Hg, mean±SD 121±19 126±21 116±15 0.02
Diastolic blood pressure, mm Hg, mean±SD 75±11 77±13 73±10 0.09
Heart rate, beats/min, median (IQR) 63 (55–72) 62 (55–71) 64 (55–73) 0.96
Body surface area, m2, 1. TTE, mean±SD 1.89±0.21 1.9±0.2 1.86±0.2 0.07
Definite ARVC/D, n (%) 53 (76%) 21 (64%) 32 (86%) 0.05
Borderline ARVC/D, n (%) 17 (24%) 12 (36%) 5 (14%) 0.05
Previous syncope, n (%) 20 (29%) 6 (18%) 14 (38%) 0.11
Previous aborted SCD, n (%) 2 (3%) 1 (3%) 1 (3%) 1.00
Previous sustained VT/VF, n (%) 40 (57%) 14 (42%) 26 (70%) 0.03
CMR data available, n (%) 18 (26%) 10 (30%) 8 (22%) 0.43
  RV ejection fraction <40%, n (%) 8 (44%) 3 (30%) 5 (63%) 0.34
  Major criterion according to 2010 TFC, n (%) 13 (72%) 6 (60%) 7 (88%) 0.31
  Minor criterion according to 2010 TFC, n (%) 2 (11%) 1 (10%) 1 (13%) 1.00
Family history of SCD <35 y, n (%) 4 (6%) 2 (6%) 2 (5%) 1.00
Endomyocardial biopsy, n (%) 5 (7%) 2 (6%) 3 (8%) 1.00
  Major criterion according to 2010 TFC, n (%) 1 (20%) 0 1 (33%) 1.00
  Minor criterion according to 2010 TFC, n (%) 1 (20%) 1 (50%) 0 1.00
Medication
  Amiodarone, n (%) 14 (20%) 5 (15%) 9 (24%) 0.15
  β-Blocker, n (%) 38 (54%) 13 (39%) 25 (68%) < 0.001
  Sotalol, n (%) 13 (19%) 5 (15%) 8 (22%) 0.24
  ACE-I/ARB, n (%) 23 (33%) 11 (33%) 12 (32%) 0.46
P values were calculated by 2-sided unpaired Student t-test (normal distribution) or Mann–Whitney U-test (skewed distribution) 
for continuous variables, and by Fisher exact test for categorical variables. Values are means±standard deviation, medians with 
interquartile ranges and numbers (percentages). 1. TTE indicates baseline transthoracic echocardiography; ACE-I/ARB, angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker; ARVC/D, arrhythmogenic right ventricular cardiomyopathy/dysplasia; CMR, 
cardiac magnetic resonance; IQR, interquartile range; MACE, major adverse cardiovascular events; SCD, sudden cardiac death; TFC, 
Revised Task Force Criteria; VF, ventricular fibrillation; and VT, ventricular tachycardia. 
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test for categorical variables. For comparison of echocardiographic 
data between baseline and follow-up, we used the paired Student t-
test (normal distribution) or the Wilcoxon signed-rank test (skewed 
distribution) for continuous variables and the McNemar test (without 
continuity correction) for categorical variables. Spearman correlation 
was performed to analyze correlations between TTE and CMR pa-
rameters. Cumulative probabilities of survival free of MACE were 
determined by the Kaplan–Meier method. We applied the Grambsch 
and Therneau method for testing the proportional hazards assumption 
for univariable Cox models. There was no evidence that proportion-
ality assumption was not fulfilled. Accordingly, baseline variables 
that were significantly associated with MACE were identified by 
univariable Cox regression analysis, and differences in survival be-
tween groups were calculated with the log-rank test. The performance 
of TAPSE and FAC for classifying an end point was measured us-
ing Harrell c-statistic, which accounts for censored measurements. 
Additionally, we calculated receiver operating characteristic curves 
and derived sensitivity and specificity for the determined cut-off 
values. The cut-off values for FAC and TAPSE were determined as 
follows: the log-rank test of all cut-off points between the 20th and 
80th percentiles was calculated, and the cut-off with the minimal ad-
justed P value was chosen according to the formula by Altman.29 For 
the purpose of this study, we were mainly interested in echocardio-
graphic variables at initial assessment that could be important to pre-
dict MACE in patients with ARVC/D. Based on the univariable Cox 
regression analysis, we performed separate bivariable analyses with 
the only 2 RV functional echocardiographic parameters (FAC and 
TAPSE) and with the 2 right-sided dimensional echocardiographic 
parameters that yielded the lowest P values in univariable analysis 
(RV end-diastolic area [RVEDA] and right atrial [RA] short-axis di-
ameter). These bivariable analyses were performed to better delin-
eate the prognostic properties of each RV functional and right-sided 
dimensional parameter on adverse outcome. The initial echocardio-
graphic assessment will guide the physician to choose an appropriate 
therapy for each individual patient based on the risk for MACE. As in 
most clinical cases, it is not appropriate to wait for an assessment of 
changes of functional and structural echocardiographic parameters to 
evaluate the patient’s risk for MACE; we have not used time-updated 
echocardiographic parameters to predict MACE. Intraclass correla-
tion (ICC) was used to quantify intra- and interobserver variability, 
with ICC values >0.75 representing good reliability of measurements. 
A 2-sided P value <0.05 was considered significant. Statistical analy-
sis was performed using R programming language (R Development 
Core Team 2009) and GraphPad Prism 5 (GraphPad Software Inc, 
La Jolla, CA).
Results
Patient Population
Of 131 patients screened in the 3 centers, 70 had a complete 
echocardiographic examination at baseline and were included 
in the study (Figure 1). All of these were referred as index 
patients with a definite or borderline diagnosis of ARVC/D 
according to the 2010 TFC. Borderline cases fulfilled 1 major 
and 1 minor (n=13) or 3 minor (n=4) criteria. Baseline charac-
teristics are provided in Table 1.
Echocardiographic Characteristics at Baseline
Echocardiographic data are presented in Tables 2 and 3. Ten 
(14%) patients had echocardiographic evidence of LV involve-
ment at baseline. When the reference values were indexed to 
BSA, 15 (21%) patients had a reduced TAPSE <7 mm/m2, 44 
(63%) patients a dilated RV >12.3 cm2/m2, 18 (26%) patients a 
dilated RA (short axis >25 and long axis >30 mm/m2), and 10 
(14%) patients a dilated LA >23 mm/m2.30 FAC correlated bet-
ter with RVEF as determined by CMR than TAPSE (r=0.480; 
P=0.05 for FAC versus RVEF; r=0.34; P=0.19 for TAPSE 
versus RVEF).
Echocardiographic Changes During Long-Term 
Follow-Up
From the whole cohort, a follow-up TTE was available in 58 
patients. Of those, 33 patients belonged to the MACE group 
and 25 patients to the favorable group (P=0.21). The median 
time between baseline TTE and follow-up TTE was 2244 
(IQR, 1099–3591; range, 95–9744) days. More patients had 
LV involvement compared with baseline (29% versus 14%; 
P=0.02). Averaged for all patients in whom a follow-up mea-
surement was available, median FAC, mean TAPSE, and mean 
TAPSE indexed to BSA decreased over time (P=0.03 for FAC; 
P=0.03 for TAPSE; P=0.01 for TAPSE/BSA, each versus 
baseline). In contrast, median RVEDA increased (P=0.001 
versus baseline). TAPSE decreased in 47% of patients, 
Table 2. Baseline Echocardiographic Variables in Patients 
With a Favorable and Those With an Adverse Outcome (MACE)
Variables
Favorable  
Outcome (n=33)
MACE  
(n=37) P Value
FAC <33%, n (%) 12 (36%) 29 (78%) <0.001
FAC <23%, n (%) 4 (12%) 17 (46%) 0.004
FAC, %, mean±SD 35±10 25±9 <0.001
TAPSE <17 mm, n (%) 5 (15%) 15 (41%) 0.03
TAPSE, mm, mean±SD 21±5 18±5 0.02
TAPSE/BSA, mm/m2, 
mean±SD
11.1±2.8 9.9±2.7 0.07
RVEDA ≥28 cm2, n (%) 9 (27%) 18 (49%) 0.09
RVEDA, cm2, median (IQR) 24.1 (21.5–28) 28 (25.3–35.6) 0.1
RVEDA/BSA, cm2/m2, 
median (IQR)
12 (11–15.4) 14.8 (13–19) 0.22
RA short axis/BSA ≥25 
mm/m2, n (%)
4 (12) 14 (38) 0.03
RA short-axis  
diameter/BSA,  
mm/m2, median (IQR)
20.4 (18.2–22.7) 22.5 (19.7–26.8) 0.17
RA short-axis diameter, 
mm, median (IQR)
39.5 (35.9–43.7) 43 (38–53.3) 0.28
RA long-axis diameter, 
mm, median (IQR)
50 (47–53.7) 52.5 (47.2–58) 0.36
RWA in <2 regions, n (%) 14 (42%) 16 (43%) 1.00
Patients with RWA, n (%) 28 (85%) 28 (76%) 0.38
Moderate/severe tricuspid 
regurgitation, n (%)
1 (3%) 7 (19%) 0.06
LV ejection fraction,  
%, mean±SD
57±7 55±13 0.39
LA diameter/BSA ≥23 
mm/m2, n (%)
2 (61%) 9 (24%) 0.09
LA diameter/BSA,  
mm/m2, mean±SD
19.4±3.1 20.2±4.1 0.35
P values were calculated by 2-sided unpaired Student t-test (normal 
distribution) or Mann–Whitney U-test (skewed distribution) for continuous 
variables, and by Fisher exact test for categorical variables. BSA indicates body 
surface area; FAC, fractional area change; IQR, interquartile range; LA, left atrial; 
RA, right atrial; RVEDA, right ventricular end-diastolic area; RWA, regional wall 
motion abnormalities defined as akinesia or dyskinesia; and TAPSE, tricuspid 
annular plane systolic excursion. 
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whereas there was no change in 24% and an increase in 29% 
(range of change, −10 to +8 mm). TAPSE adjusted for BSA 
decreased in 45% of patients, whereas there was no change in 
29% and an increase in 26% (range of change, −5 to +4 mm/
m2). FAC decreased in 57% of patients, whereas there was 
no change in 4% and an increase in 39% (range of change, 
−33% to +18%). RVEDA increased in 63% of patients, no 
change in 11%, and a decrease in 26% (range of change, −15 
to +25 cm2). Figure 3 depicts the data for FAC and TAPSE 
at baseline and their changes during long-term follow-up in 
patients from whom measurements of both parameters were 
available. A significant positive correlation between baseline 
FAC and TAPSE (r=0.5; P<0.001) and a negative correlation 
between baseline FAC and baseline right chamber dimen-
sions (r=−0.57; P<0.001 for FAC versus RVEDA; r=−0.44; 
P<0.001 for FAC versus RA short axis/BSA) were observed. 
There was no evidence for an association between an impaired 
TAPSE and subtricuspidal regional wall motion abnormalities 
(P=1.0).
Predictors of Clinical Outcome
Over a median follow-up period of 5.3 (IQR 1.8–9.8) years, 
37 (53%) patients experienced MACE (Table 4). Median 
 follow-up was not significantly different between patients 
with favorable versus those with an adverse outcome (4.4 
years; IQR 1.6–8.1 versus 6.3 years; IQR 2.1–10.5 years, 
respectively; P=0.48). No patient died. Heart transplantation 
was performed in 5 patients (due to incessant VT/VF com-
bined with heart failure in 3 patients and heart failure only in 
2 patients). The most frequent MACE were survived sustained 
VT (67%) and VF (19%). Thirty-one (63%) of 49 patients 
with an ICD experienced an appropriate ICD intervention. 
This intervention was because of VT in 24 patients and VF 
in 7 patients. Table 2 shows baseline echocardiographic 
parameters in patients with favorable outcome and those with 
MACE. Variables analyzed as potential predictors of MACE 
are presented in Table 5. A lower FAC and TAPSE as well as 
an increased RVEDA and RA short-axis diameter were identi-
fied as univariable predictors (Table 5). In bivariable analyses 
stratified into functional and dimensional echocardiographic 
parameters, FAC (functional parameter), RVEDA, and RA 
short-axis diameter (dimensional parameters) remained inde-
pendent predictors of MACE. A reduced FAC constituted 
the strongest predictor of MACE (hazard ratio, 1.08 per 1% 
decrease; 95% confidence interval [CI], 1.04–1.12; P<0.001) 
on bivariable analysis. Consistent with this observation, Har-
rell c-statistic for FAC equaled 0.67 and for TAPSE 0.61, dem-
onstrating that the measurement of baseline FAC had a better 
predictive value compared with baseline TAPSE. Figure 4 
illustrates the results of the receiver operating characteristic 
analysis for distinguishing patients with MACE from those 
without. For baseline FAC, a sensitivity >80% for predict-
ing MACE was obtained at a cut-off <23% (sensitivity, 88%; 
95% CI, 73–95%) and for baseline TAPSE at a cut-off <17 
mm (sensitivity, 85%; 95% CI, 69–93%), yet both parameters 
displayed a limited specificity for these cut-off values (FAC, 
46%; 95% CI, 31–62%; TAPSE, 41%; 95% CI, 26–57%). 
Patients with a FAC <23% or a TAPSE <17 mm had a cumu-
lative probability for MACE ≈75% after 2 years (Figure 5), 
which was higher than for patients with a FAC ≥23% (P log-
rank unadjusted and adjusted <0.001) and a TAPSE ≥17 mm 
(P log-rank unadjusted=0.02, adjusted=0.19).
Reproducibility
For interobserver variability, ICC values were 0.50 (95% CI, 
0.18–0.72) for FAC and 0.83 (95% CI, 0.67–0.91) for TAPSE, 
whereas for intraobserver variability, ICC values were 0.59 
(95% CI, 0.30–0.86) for FAC and 0.86 (95% CI, 0.72–0.93) 
for TAPSE.
Discussion
In this longitudinal study, we analyzed a relatively large 
cohort of patients with ARVC/D from 3 tertiary care centers 
regarding their long-term clinical outcome based on echocar-
diographic findings at initial presentation. Our study provides 
evidence that echocardiographic parameters can be applied to 
predict the clinical outcome in ARVC/D. The main findings 
are as follows: (1) FAC at baseline is the strongest echocardio-
graphic predictor of MACE; (2) reduced TAPSE and increased 
Table 3. Echocardiographic Variables at Baseline and 
Follow-Up
Variables
First TTE  
(n=70)
Follow-Up TTE  
(n=58) P Value
Patients with RWA, n (%) 56 (80%) 52 (90%) 0.01
RWA of subtricuspid  
region, n (%)
47 (67%) 50 (86%) <0.001
RWA in ≥2 regions, n (%) 40 (57%) 42 (72%) 0.16
TAPSE, mm, mean±SD 19.7±5.4 18.8±5.4 0.03
TAPSE <17 mm, n (%) 20 (29%) 20 (34%) 0.48
TAPSE/BSA, mm/m2, 
mean±SD
10.5±2.8 9.9±2.9 0.01
RV FAC, %, median (IQR) 30 (20–38.3) 26.5 (20.3–34) 0.03
RV FAC <33%, n (%) 41 (59%) 38 (66%) 0.64
LV ejection fraction, %, 
median (IQR)
57.5 (51–64) 55 (47.78–63) 0.04
RVEDA, cm2, median (IQR) 26.1 (22.5–29.6) 29.8 (24.7–35) 0.001
RVEDA/BSA, cm2/m2, 
median (IQR)
13.6 (11.7–17.1) 15.6 (13.2–18.8) 0.003
LA diameter/BSA, mm/m2, 
median (IQR)
20 (17.3–21.6) 19.4 (17.9–21.7) 0.86
RA short-axis diameter, 
mm, median (IQR)
42 (36–47) 42 (36–53) 0.29
RA short-axis diameter/BSA, 
mm/m2, median (IQR)
21.4 (19.3–25.3) 22.2 (19.1–27.7) 0.54
RA long-axis diameter,  
mm, median (IQR)
51 (47–56) 53 (48–57) 0.5
RA long-axis diameter/BSA, 
mm/m2, median (IQR)
27 (23.9–30.1) 27.4 (23.2–31.1) 0.9
Moderate/severe tricuspid 
regurgitation, n (%)
8 (14%) 6 (10%) 0.16
P values were calculated by 2-sided paired Student t-test (normal distribution) 
or Wilcoxon signed-rank test (skewed distribution) for continuous variables and 
by McNemar test for categorical variables. BSA indicates body surface area; 
FAC, fractional area change; IQR, interquartile range; LA, left atrial; RA, right 
atrial; RVEDA, right ventricular end-diastolic area; RWA, regional wall motion 
abnormalities defined as akinesia or dyskinesia; TAPSE, tricuspid annular plane 
systolic excursion; and TTE, transthoracic echocardiography.
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right-sided chamber dimensions at baseline are associated 
with an increased risk of MACE; (3) TAPSE is associated 
with lower intra- and interobserver variability compared with 
FAC; and (4) on average, both FAC and TAPSE decrease dur-
ing long-term follow-up, whereas right-sided chamber dimen-
sions increase.
Natural History
Previous echocardiographic studies have demonstrated that 
RV dilation and reduced regional or global RV function are 
important features of ARVC/D.31–33 Our study underscores that 
ARVC/D is a progressive disease.8,31,34 During long-term follow-
up, right chamber dimensions significantly increased, whereas 
both FAC and TAPSE decreased. Moreover, LV involvement 
increased by 2.3-fold compared with baseline, with almost one 
third of patients demonstrating biventricular disease at follow-
up. In line with previous findings from a smaller ARVC/D 
cohort from Scandinavia, FAC and TAPSE did not decrease, 
and RVEDA did not increase in a substantial proportion of 
patients. This reflects some heterogeneity in the individual dis-
ease course but may also be related to variability in the mea-
surement of those echocardiographic parameters.34 Our results 
differ from those of a smaller Italian ARVC/D cohort in which 
RVEF and RV end-diastolic volume as determined by 2D TTE 
did not change significantly between baseline and long-term 
follow-up.35 A likely explanation for this discrepancy may be 
related to differences in the assessment of RV function and 
dimension, as well as a lack of power to detect significant dif-
ferences occurring over time due to small sample size.
Predictive Role of Echocardiographic Variables
Different ARVC/D cohorts independently confirmed that 
spontaneous ventricular tachyarrhythmias, syncope, heart fail-
ure, LV involvement, and inducibility of sustained ventricular 
arrhythmias constitute the risk factors for MACE.8,9,12–14,28,36 Yet 
previous studies have yielded conflicting evidence regarding 
the usefulness of RV function and dimension for risk predic-
tion in ARVC/D.7–15,37 Controversial findings by others may be 
related to different study methodologies, divergent imaging 
modalities, and heterogeneous patient cohorts. Neither occur-
rence nor severity of RV disease was defined homogenously 
throughout these studies. A large international multicenter 
study, Multidisciplinary Study of Right Ventricular Dysplasia, 
has defined diffuse RV involvement as severe regional involve-
ment in ≥2 RV regions or an RVEF ≤45%.12 Yet imaging modal-
ities to measure these parameters have not been standardized 
across different centers.19 Data about the predictive role of FAC 
reflecting RVEF in a single 2D plane acquired in the 4CV are 
scarce in patients with ARVC/D, and 3 previous studies ana-
lyzing the predictive role of FAC in ARVC/D came to different 
conclusions.9,14,15 Echocardiographic assessment of RV dimen-
sion and function is challenging because of the complex RV 
geometry, and both FAC and TAPSE do not always correlate 
well with the more accurate 3-dimensional volumes and EF 
obtained by CMR.16–20 This is particularly true for FAC, which 
depends on an optimal image quality. FAC also does not fully 
reflect the regional function of the RV outflow tract and subtri-
cuspid area that are often involved in ARVC/D.14 Furthermore, 
FAC consistently displayed higher intra- and interobserver 
variability compared with TAPSE in previous studies as well 
as the present study, which may also be related to the fact that 
we did not exclude any patient due to difficulties in measuring 
FAC. Yet both parameters showed good ICC in our analysis.23,38 
Despite these limitations, the current study demonstrates that 
even small reductions in FAC were associated with MACE, 
Table 4.  Specification of Major Adverse Cardiovascular 
Events (MACE) During Follow-Up
MACE n=37
Cardiac death 0
Heart transplantation 2 (5%)
Ventricular fibrillation 7 (19%)
Sustained ventricular tachycardia 25 (67%)
Arrhythmic syncope 3 (8%)
Values are numbers (percentages).
Figure 3. Individual data (black lines) and average values (red line) for tricuspid annulus plane systolic excursion (TAPSE; left) and right 
ventricular fractional area change (FAC; right) at baseline and their change during long-term follow-up from patients in whom a follow-up 
transthoracic echocardiography (n=58) was available. P values were calculated by 2-sided paired Student t-test (normal distribution) or 
Wilcoxon signed-rank test (skewed distribution).
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and that a reduced FAC was the strongest predictor of MACE 
on univariable and bivariable Cox regression analysis. Of note, 
an FAC >33%, which is proposed as the lower normal range 
in the current guidelines,19 still conferred a 3-fold increased 
risk for adverse events and supports the 2010 TFC, in which 
the combination of regional wall motion abnormalities and an 
FAC between 33% and 40% are considered minor criteria for 
ARVC/D diagnosis.12
Although angle-dependent, TAPSE can easily be deter-
mined by M-mode echocardiography, is less dependent on 
image quality, and constitutes a robust and reproducible 
parameter for the echocardiographic assessment of RV func-
tion in ARVC/D. It also correlates well with RVEF deter-
mined by CMR or angiography.16,20–23,39,40 The low intra- and 
interobserver variability for TAPSE in the current study is 
consistent with those previous findings. TAPSE has the poten-
tial to discriminate well between patients with ARVC/D and 
healthy probands.18,33 Although TAPSE has evolved as an 
important prognostic parameter in other cardiac pathologies 
such as pulmonary hypertension, myocarditis, and dilated 
cardiomyopathy,16,17,41 it has not been studied as a prognostic 
marker in ARVC/D. To our knowledge, our study is the first 
Figure 4. Results of the receiver operating charac-
teristic analysis for tricuspid annulus plane systolic 
excursion (TAPSE) and fractional area change 
(FAC; n=70). TAPSE <17 mm and FAC <23% at 
baseline provided the best sensitivity and speci-
ficity for predicting major adverse cardiovascular 
events in patients with arrhythmogenic right ven-
tricular cardiomyopathy/dysplasia. Numbers shown 
in the black box indicate the corresponding cut-off 
values for TAPSE and FAC, respectively.
Table 5. Baseline Variables Associated With Major Adverse Cardiovascular Events
Variables
Univariable Analysis Bivariable Analysis Bivariable Analysis
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
FAC <33% 3.12 (1.42–6.87) 0.005
FAC <23% 4.49 (2.25–8.97) <0.001
FAC, %, per unit decrease 1.08 (1.04–1.12) <0.001 1.08 (1.04–1.12) <0.001
TAPSE <17 mm 2.15 (1.10–4.17) 0.02
TAPSE, mm, per unit decrease 1.05 (0.99–1.12) 0.09 1.01 (0.94–1.08) 0.73
TAPSE/BSA, mm/m2, per unit decrease 1.09 (0.98–1.2) 0.12
RVEDA ≥28 cm2 2.96 (1.48–5.91) 0.002
RVEDA, cm2, per unit increase 1.05 (1.02–1.09) <0.001 1.05 (1.01–1.08) 0.004
RVEDA/BSA, cm2/m2, per unit increase 1.08 (1.03–1.14) 0.002
RA short axis/BSA ≥25 mm/m2 2.03 (1.03–3.99) 0.04
RA short axis/BSA, mm/m2, per unit increase 1.06 (1.01–1.12) 0.02
RA short axis, mm, per unit increase 1.04 (1.01–1.07) 0.01 1.03 (1.00–1.06) 0.037
RA long axis, mm, per unit increase 1.03 (1.00–1.06) 0.06
RWA in <2 regions 0.48 (0.22–1.08) 0.08
Absence of RWA 0.64 (0.24–1.72) 0.38
Moderate/severe tricuspid regurgitation 1.99 (0.71–5.55) 0.19
LV ejection fraction, %, per unit decrease 1.01 (0.98–1.04) 0.54
LA/BSA ≥23 mm/m2 1.93 (0.88–4.25) 0.10
LA/BSA, mm/m2, per unit increase 1.03 (0.95–1.12) 0.46
Age per year increase 0.99 (0.97–1.01) 0.43
Sex (HR for women vs men) 0.77 (0.38–1.56) 0.47
Definite ARVC/D 1.04 (0.47–2.27) 0.93
P values were calculated by univariable and bivariable Cox-regression. ARVC/D indicates arrhythmogenic right ventricular cardiomyopathy/dysplasia; BSA, body 
surface area; CI, confidence interval; FAC, fractional area change; HR, hazard ratio; LA, left atrial; LV, left ventricular; RA, right atrial; RVEDA, right ventricular end-
diastolic area; RWA, regional wall motion abnormalities; and TAPSE, tricuspid annular plane systolic excursion.
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to demonstrate that TAPSE may be valuable for predicting 
MACE in ARVC/D. A value of TAPSE <17 mm best identi-
fied patients with MACE. However, TAPSE was inferior to 
FAC with regard to its predictive value and also correlated less 
well with RVEF as determined by CMR, which may well be 
related to the fact that TAPSE only represents the longitudinal 
systolic movement of the RV lateral free wall and hence does 
not reflect the entire RV systolic function. This property may 
constitute a particular drawback in patients with ARVC/D, 
which can affect multiple regions of the RV. Such a regional 
heterogeneity in systolic function is certainly better reflected 
by FAC. Another new finding of our study is the predictive 
value of RA dilation as previously shown in Eisenmenger 
Syndrome.30,42 This finding is in line with a recent study show-
ing a prognostic impact of significant tricuspid regurgitation 
in ARVC/D.14
Limitations
This study analyzing patient data from 3 Swiss tertiary care 
centers may have limitations in patient selection and risk 
stratification by its observational nature. Of note, we studied 
a rather high-risk cohort of patients with ARVC/D, given the 
fact that 57% of our patients had a sustained episode of VT/VF 
before baseline echocardiography and given the observed high 
MACE rates. Definite disease was more common in the MACE 
group at baseline, although definite disease was not associated 
with MACE in Cox regression analysis. Thus, our data may 
not be generalizable to other, potentially lower-risk ARVC/D 
populations. Yet we analyzed whether the patients who were 
excluded from the final analysis constituted a  lower-risk popu-
lation than those included. In patients with a borderline and 
definite diagnosis of ARVC/D, MACE were observed in 17 
of 34 (50%) excluded patients compared with 37 of 70 (53%) 
included patients, minimizing the risk of selection bias toward 
a higher-risk population within our ARVC/D cohort. Although 
the studied cohort was not small for patients with ARVC/D, 
the sample size limits the ability to control for all confound-
ers in multivariable analysis. Although median follow-up was 
not significantly different between patients with a favorable 
outcome and those with MACE, from a clinical perspective, 
we cannot fully exclude that the median difference of 1.9 
years may have contributed to more adverse events observed 
in the MACE group and that MACE may also have occurred 
in the favorable group if follow-up period would have been 
equal. When RV function is regionally impaired in areas not 
imaged in the 4CV, such as the RV outflow tract, FAC may 
be an imperfect measure of RV systolic function. Therefore, 
FAC may perform less well as a predictor of MACE in those 
patients. Furthermore, the assessment of RV function with 
FAC and TAPSE may be limited by the acoustic shadowing of 
ICD leads. The advent of tissue Doppler imaging and recently 
strain imaging and 3-dimensional tools may improve both 
diagnosis and risk stratification in ARVC/D,15,18,33,43 although 
their use is still hampered by wide variations, noise artifacts, 
limited availability, and intervendor variations.18,43–45
Conclusions
This long-term observational study indicates that TAPSE and 
dilation of right-sided cardiac chambers are associated with 
an increased risk for MACE in patients with ARVC/D with 
advanced disease and a high risk for adverse events. However, 
FAC is the strongest echocardiographic predictor of adverse 
Figure 5. Kaplan–Meier analysis (n=70) of freedom from major 
adverse cardiovascular events from baseline transthoracic 
echocardiography stratified by a tricuspid annulus plane sys-
tolic excursion <17 mm (top; unadjusted P=0.02 and adjusted 
P=0.19), a fractional area change (FAC) <23% (middle; unad-
justed and adjusted P<0.001), and a right atrial (RA) short axis/
body surface area (BSA) ≥25 mm/m2 (bottom; P=0.037; prespec-
ified cut-off value, thus adjustment not necessary).
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outcome in these patients. Our data advocate a role for TTE in 
risk stratification in patients with ARVC/D, although our results 
may not be generalizable to lower-risk ARVC/D cohorts.
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CLINICAL PERSPECTIVE
Data on risk stratification in arrhythmogenic right ventricular cardiomyopathy/dysplasia are scarce. Moreover, the natural 
history of arrhythmogenic right ventricular cardiomyopathy/dysplasia is still being defined. Current guidelines suggest that 
severe right ventricular (RV) dilation and extensive RV involvement are risk factors for an adverse outcome. However, the 
different stages of RV dilation and RV involvement are not well defined. Our study helps to understand the clinical course 
of the disease, as it generally demonstrates an increase in RV area and a decline in RV function during long-term  follow-up. 
We demonstrate that patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia who have a RV fractional 
area change <23% and a tricuspid annulus plane systolic excursion <17 mm, transthoracic echocardiographic measure-
ments that can noninvasively be obtained by the practicing cardiologist at initial assessment, are at increased risk for an 
adverse outcome and may benefit from an implantable cardioverter defibrillator. If these novel findings can be confirmed 
in other populations with arrhythmogenic right ventricular cardiomyopathy/dysplasia, they will provide the necessary evi-
dence for considering prophylactic implantable cardioverter defibrillator insertion in such patients.
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